Ningping Feng

Ningping Feng

UNVERIFIED PROFILE

Are you Ningping Feng?   Register this Author

Register author
Ningping Feng

Ningping Feng

Publications by authors named "Ningping Feng"

Are you Ningping Feng?   Register this Author

34Publications

810Reads

7Profile Views

Expression of HDAC2 but Not HDAC1 Transcript Is Reduced in Dorsolateral Prefrontal Cortex of Patients with Schizophrenia.

ACS Chem Neurosci 2017 03 13;8(3):662-668. Epub 2016 Dec 13.

Human Brain Collection Core, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, United States.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acschemneuro.6b00372
Publisher Site
http://dx.doi.org/10.1021/acschemneuro.6b00372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436730PMC
March 2017

Differential effects of common variants in SCN2A on general cognitive ability, brain physiology, and messenger RNA expression in schizophrenia cases and control individuals.

JAMA Psychiatry 2014 Jun;71(6):647-56

Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland2Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland8Depar.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamapsychiatry.2014.157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160812PMC
June 2014

Incomplete penetrance of NRXN1 deletions in families with schizophrenia.

Schizophr Res 2014 May 26;155(1-3):1-7. Epub 2014 Mar 26.

Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, 855 North Wolfe St, Suite 300, Baltimore, MD 21205, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2014.02.023DOI Listing
May 2014

IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo.

Cancer Immunol Immunother 2010 Jun 13;59(6):805-17. Epub 2009 Dec 13.

Research and Development Department, Lorus Therapeutics Inc., 2 Meridian Road, Toronto, ON, M9W 4Z7, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-009-0802-8DOI Listing
June 2010

The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/beta junction mediates cell killing.

Int J Cancer 2009 Jan;124(1):46-54

National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.23910DOI Listing
January 2009

Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors.

Cancer Immunol Immunother 2008 Dec 20;57(12):1757-69. Epub 2008 Mar 20.

Research and Development Department, Lorus Therapeutics Inc., 2 Meridian Road, Toronto, ON, Canada, M9W 4Z7.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-008-0502-9
Publisher Site
http://dx.doi.org/10.1007/s00262-008-0502-9DOI Listing
December 2008

Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo.

Int Immunopharmacol 2007 Oct 26;7(10):1350-9. Epub 2007 Jun 26.

Research and Development Department, Lorus Therapeutics Inc., 2 Meridian Road, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2007.06.001DOI Listing
October 2007

Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages.

Cancer Immunol Immunother 2005 Nov 13;54(11):1115-26. Epub 2005 May 13.

Research and Development Department, Lorus Therapeutics Inc., 2 Meridian Road, Toronto, ON, Canada M9W4Z7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-005-0698-xDOI Listing
November 2005

Co-occurrence of two partially inactivating polymorphisms of MC3R is associated with pediatric-onset obesity.

Diabetes 2005 Sep;54(9):2663-7

Unit on Growth and Obesity, National Institutes of Health, 10 Center Dr., Hatfield CRC, Rm 1-3330, MSC 1103, Bethesda, MD 20892-1862, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1861848PMC
http://dx.doi.org/10.2337/diabetes.54.9.2663DOI Listing
September 2005

Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

J Clin Endocrinol Metab 2005 Jun 1;90(6):3251-61. Epub 2005 Mar 1.

Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2004-2194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1350765PMC
June 2005

NK cell activation and tumor infiltration are involved in the antitumor mechanism of Virulizin.

Cancer Immunol Immunother 2005 Mar 17;54(3):229-42. Epub 2004 Sep 17.

Research and Development Department, Lorus Therapeutics Inc., 2 Meridian Road, Toronto, ON, Canada, M9W 4Z7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-004-0582-0DOI Listing
March 2005

Macrophages play a critical role in the anti-tumor activity of Virulizin.

Int J Oncol 2003 Nov;23(5):1341-6

R&D Department, Lorus Therapeutics Inc., Toronto, Ontario M9W 4Z7, Canada.

View Article

Download full-text PDF

Source
November 2003

Sequence variants of the POMC gene and their associations with body composition in children.

Obes Res 2003 May;11(5):619-24

Unit on Growth and Obesity, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland 208*2-1862, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1038/oby.2003.89
Publisher Site
http://dx.doi.org/10.1038/oby.2003.89DOI Listing
May 2003

Preclinical efficacy of Virulizin in human breast, ovarian and prostate tumor models.

Anticancer Drugs 2003 Apr;14(4):289-94

R & D Department, Lorus Therapeutics Inc, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200304000-00006DOI Listing
April 2003

Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts.

Cancer Chemother Pharmacol 2003 Mar 5;51(3):247-55. Epub 2003 Mar 5.

Lorus Therapeutics Inc, 2 Meridian Road, ON M9W 4Z7, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-002-0559-7DOI Listing
March 2003

[Variation of gene at the apolipoprotein C III locus with the changes of serum lipid profile in school-aged children].

Wei Sheng Yan Jiu 2002 Aug;31(4):241-3

Department of Nutrition and Food Hygiene, Health Science Center, Peking University, Beijing 100083, China.

View Article

Download full-text PDF

Source
August 2002